FIELD: biotechnology.
SUBSTANCE: disclosed are protein conjugates containing polyubiquitin, a carrier linked through a linker to polyubiquitin, and four biomolecules linked through a linker to polyubiquitin and a carrier. In addition, present invention relates to a pharmaceutical composition containing a protein conjugate, and a method for preventing or treating non-alcoholic steatohepatitis, fatty liver disease, liver fibrosis, liver cirrhosis, liver cancer, obesity, or diabetes.
EFFECT: invention provides higher activity and improved therapeutic action of biomolecules.
16 cl, 55 dwg, 37 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
| METHOD FOR OBTAINING BIFUNCTIONAL PROTEINS AND THEIR DERIVATIVES | 2018 |
|
RU2795970C2 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
| COMPOSITIONS AND METHODS FOR CONTROLLING ACCUMULATION OF ADIPOSE TISSUE | 2014 |
|
RU2711478C2 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| METHODS FOR TREATMENT OF SEVERE INSULIN RESISTANCE BY INTERRUPTING GLUCAGON RECEPTOR SIGNAL TRANSMISSION | 2017 |
|
RU2772508C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2741087C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
